Biz New Orleans
South Rampart Pharma Hopes to Develop Safer Pain Medications
June 14, 2022
South Rampart Pharma, a clinical-stage life science company advancing medications for the treatment of pain and fever, announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant. The “fast-track” combined Phase I/II award provides for $1.9 million of funding to support the ongoing clinical development of the company’s lead small molecule, SRP-3D (DA), a novel non-opioid therapeutic candidate. South Rampart Pharma currently is completing the single ascending dose phase of the Phase 1 clinical trial of SRP-3D (DA) and remains on track to report topline results from the study in the third quarter of 2022.